The Board of Directors of EQL Pharma AB (publ) has resolved to evaluate the conditions for listing the company’s share on Nasdaq Stockholm’s main list. The list change is expected to take place during the last quarter of 2020. EQL Pharma’s Board of Directors and management will now initiate the work required to prepare the company for a listing on Nasdaq Stockholm.
EQL Pharma’s share has been listed on Spotlight Stock Market since 2013 and in Spotlight’s new segment Next since October 31, 2019. Companies traded in this segment follow stricter rules regarding, among other things, accounting principles than other companies listed on Spotlight Stock Market. The requirements correspond in several respects to the requirements on Nasdaq Stockholm’s main list.
EQL Pharma has engaged HWF Advokater as legal advisor for the planned list change.
